ANTIMICROBIAL NANO-TECHNOLOGY

ZOONO GROUP LIMITED INVESTOR OVERVIEW

MARCH 2017

ZOONO®

DISCLAIMER

This Investor presentation has been prepared solely for the purpose of assisting recipients in deciding whether to investigate further a possible investment in the securities of Zoono Group Limited and may only be used for that purpose.

Market size estimates are based on available research but no warranty can be given to their accuracy. This Investor presentation is not intended to provide the sole or principal basis of an investment decision or any other risk evaluation and may not be considered as a recommendation by Zoono Group Limited, JB Advisory Pty Ltd or any Wother person in connection with an investment in Zoono Group Limited. Any recipient should determine its interest in acquiring securities in Zoono Group Limited on the basis of the Investor presentation and independent investigations that it considers necessary or desirable.


An investment in should be considered a highly speculative investment that is subject to significant risks. Any party considering an investment in Zoono Group Limited should seek independent financial advice. This Investor presentation has not been, and will not be, lodged with ASIC.



AGENDA

- Who is Zoono & What do we do
- Board
- History & Key Facts
- How Zoono works
- The Proof
- Market Opportunity
- Products
- Financials, raising & use of funds
- Pro Forma Capital Structure
- Timetable
- Summary





WHO IS ZOONO

- New Zealand Company specialising in the development, manufacture and sales of a range of unique nano-technology based antimicrobial sanitising products
- Zoono was founded in 2009 by Paul Hyslop
- Zoono sells via Distributors globally
- Zoono's formulations have numerous approvals including US Food and Drug Administration (FDA) compliance
- Zoono has over 50 independent laboratory test results from third party laboratories across the globe operating under ISO (International Standards Organisation) or GLP (Good Laboratory Practice) standards

WHAT IS ZOONO

ZOONO is Antimicrobial Nano-Technology: using intelligent molecules to actively and consistently reduce pathogen loads on surfaces using physics ***(mechanical)*** instead of chemistry ***(chemicals)***

Uses natural organic compounds – silicon, alcohol hydrocarbons and nitrogen; heat, stir and you have Zoono (active ingredient 3-trimethoxysilyl propyl dimethyl octadecyl ammonium chloride)

THERE IS NO MORE POWERFUL, LONGER-LASTING ANTIMICROBIAL TECHNOLOGY ON THE MARKET TODAY

TRADITIONAL DISINFECTION:

- Dissolves, dehydrates or “poisons” germs
- Only effective while wet
- **No residual efficacy**
- Highly Toxic
- Highly corrosive
- Labor intensive – regular repeat application
- Different products for different pathogens

ZOONO:

- Physically lyses /impales germs
- Most effective when DRY
- **Persistent Efficacy**
- Virtually Non-Toxic
- Non-Corrosive
- Labor saving
- Physical Kill = broad spectrum kill

BOARD OF DIRECTORS

PAUL HYSLOP

Managing Director and founder of Zoono and has an extensive background in business, owning his first business at 19 which grew to employing 60 staff. Paul then pursued his passion for flying and after several years as an instructor and pilot he re-entered the commercial sector progressing to being a Director of several companies before founding Zoono in 2008.

JOHN LAMB

Executive Chairman has extensive global pharmaceutical Company experience and is currently Non-Executive Director of dual ASX / NZX listed AFT Pharmaceuticals Ltd. Jon has an extensive history of executive and advisory roles including Zespri International Ltd and Fletcher Challenge, and is a Member of the Institute of Directors and the Chartered Institute of Marketing.


DON CLARKE

A director of several listed and unlisted companies, Don has advised leading corporate clients on broad corporations law issues focused on equity capital markets, private equity, mergers and acquisitions and corporate restructures. Don has acted in more than 50 ASX listings, private equity expansion capital funding programs, IPOs, privatisations of Government business units, and led many share and asset acquisitions and trade sales, both in Australia and offshore.

ELISSA HANSEN

An experienced Chartered Secretary with over 15 years' experience in advising management and boards on investor relations, governance, compliance and other corporate issues, Elissa is an associate member of the Institute of Chartered Secretaries Australia and Graduate Member of the Australian Institute of Company Directors, and has a Bachelor of Commerce and a Graduate Diploma in Applied Corporate Governance.

HISTORY


ZOONO®
MILESTONES
1930
Technology discovered by German scientists
1950
Developed as a textile additive but heavily stabalised in methanol
1980
Technology refined further
1990
Re-engineered into a water based product but with a low shelf life
2008
Zoono established in NZ. To develop into a 9th generation, food safe, non-toxic product. Highly effective against bacteria and viruses
2012
TGA, NZFSA and AsureQuality approvals gained in Australasia
2013
Rollout of Zoono global distributor network
2013
Development retail brands shelf life of 3 years achieved
2014
Zoono products now sold in 20 countries
2015
Zoono skin products Food and Drug Administration Compliant and comply with the FDA monograph, surface product (Z-71) registered with the US Environmental Protection Agency.
2016
Hospital grade germ killer approved by the Therapeutic Goods Authority in Australia



KEY FACTS


ZOONO DELIVERS:

- **Persistently hygienic environment – on skin and surfaces**
- **Reduces costs by mitigating application labor and product**

- **Physical vs. Chemical "Kill"** - 'pins' attract and physically kill bacteria and because it does not kill by toxicity or poisoning, organisms cannot adapt: **NO Mutation = NO Superbugs.**
- **Persistent Efficacy:** effectiveness for up to 24 hours on skin and up to 28 days on surfaces.
- **Water-based** - not caustic, Low / No VOC (Volatile Organic Compounds)
- **Non-Toxic** – active ingredient is less toxic than Vitamin C (LD50)
- **Safe** - non flammable, not caustic, dermatologically tested
- **Non-leaching** – Zoono **bonds permanently** to the target surface, product cannot leach
- **Easy to use** – no dilution, ready to use

No product available today can offer this combination of benefits with data to support claims.

HOW IT WORKS



A.
Long Molecular Chain (18)
+ Nitrogen
Silane Base
3-Trimethoxy silyl propyl dimethyl octadecyl ammonium chloride
A. The Zoono molecule with long, pointed chain of atoms'
B. Microbe landing on a microscopic bed of spikes
C. Destruction of the microbe
B.
C.

THE PROOF

TARGET ORGANISM	BACTERIA % REDUCTION	AFTER 14 DAYS	AFTER 28 DAYS
Staphylococcus aureus	99.99	99.97	99.98
Pseudonomas aeruginosa	99.98	99.96	99.96
Escherichia coli	99.99	99.98	99.98
Proteus vulgaris	99.99	99.93	99.93
Methycillin Resistant Staphylococcus aureus	99.99	99.98	99.96
Vancomycin Resistant Enterococcus (VRE)	99.97	99.97	99.96
Citrobacter Freudii	99.99	99.98	99.98

THE PROOF

Test was conducted by Abbott Analytical – subjects had one hand treated with Zoono and the other simply washed with soap & water to start and they were instructed to go about their daily lives. Subjects' hands were cultured at **2 hour intervals for 24 hours** and these are the results.



Colored bars indicate pathogen growth on Untreated hands

Note: virtually nonexistent growth on Treated Hands

MARKET OPPORTUNITY

THE PROBLEM: Infectious Disease / Pathogen Management is defined by product limitations:

CHEMICAL DISINFECTION

- Only effective while wet
- **No residual efficacy**
- Highly Toxic
- Highly corrosive
- Labor intensive – regular repeat application
- Different products for different pathogens

With current technologies, the hygienic state of any surface is intermittent

MECHANICAL DISINFECTION (UV LIGHT)

- Only effective while light is ON
- **No residual efficacy**
- Highly Toxic – room must be vacant
- Labor intensive
- Logistically cumbersome
- Expensive


CURRENT SOLUTIONS

- Increase product potency/frequency of use

Both have toxicity, cost and labor issues with marginal impact to hygienic state

None offer any improvement in persistence

"More of the same is not the answer"



PRODUCTS - HOME

- Kitchen Surface Sanitiser and Protectant
- Bathroom Surface Sanitiser, Mould Killer and Protectant
- Room Deodoriser and Protectant
- Toilet Seat Sanitiser and Protectant
- Remove odour and pet smells



PRODUCTS - PERSONAL

- GermFree24 Hand Sanitiser 50ml or 500ml Family Pack
- Zoono Athlete's Foot Treatment
- Zoono Skin Clear Acne Treatment
- Zoono Femme Personal Hygiene
- Zoono Personal Deodorant



COMMERCIAL / INDUSTRIAL

FOGGING



For Offices, Schools, Banks, Homes, Public facilities, Child and Aged Care and Hospitals.

FOOD



Use during the Manufacture, Packaging, Transport, Preparation of food and beverages.

TEXTILES



To protect against mould, bacterial odour and fungi.

FARM



For use in Orchards, Vineyards, Poultry Sheds & Livestock

PRODUCT SOLD BY COUNTRY

Z-71 Microbe Shield Surface Sanitiser	New Zealand, Australia, USA, Korea, China, Hong Kong, South Africa, Nigeria, UAE, KSA, India, Egypt, Peru, Chile, UK, Kuwait, Qatar, Norway, Germany, Jordan, Guam, Singapore, Malaysia, Taiwan, Turkey, Canada, Oman, Iran
ZoonoTex	New Zealand, Australia, USA, Japan, Korea, China
GermFree 24 Hand Sanitiser	New Zealand, Australia, USA, Korea, China, Hong Kong, South Africa, Nigeria, UAE, KSA, India, Egypt, Peru, Chile, UK, Kuwait, Qatar, Norway, Germany, Jordan, Singapore, Malaysia, Taiwan, Turkey, Canada, Oman, Iran
Zoono Femme	USA, China
Zoono Foot Guard	New Zealand, USA, China
Zoono Skin Clear	New Zealand, USA, China, Singapore, Malaysia
Zoono Odour Guard	New Zealand, USA, China
Zoono Room Deodoriser	New Zealand
Zoono Mould Guard	New Zealand, China
Zoono ZAM Mould Killer	New Zealand, China
Zoono Mini Foggers	New Zealand, Australia, USA, China, Canada
Zoono Wet Wipes	China

CURRENT OPPORTUNITIES

PARNTER	OPPORTUNITY
SMI Japan	Kobayashi - Textiles for manufacturing antimicrobial socks – 3 year successful trials completed, initial order being prepared, due April
ZOONO USA Raised $3m in February 2017 to support increased demand	CVS Pharmacy (8800 outlets) to increase order volume by >50% SpecOps (Zoono partner) expect initial order from US Federal Agency Discussions with additional retail chain 8000 outlets 2 large Hospital/Healthcare groups
Clear Facilities NZ/Aust/UK Raised $1.5m in 2016 to fund growth	Increased orders for existing NZ clients Current trial with national fast food chain in Australia Transport Department in UK trialing Zoono
Permagard	Increased “fogger” orders for Mercedes Benz, Virgin and Qantas National supermarket for retail products – samples provided Early discussions with UK auto distributor – trial samples provided
EMA Liquid Health South Africa	Health Department, first order received $160k October 2016, expect regular orders every 3-4 months of same size. 2nd order received

HISTORICAL FINANCIALS

Profit & Loss for the years ended	31-Mar-16 NZ$	31-Mar-15 NZ$
Sales Revenue	944,877	845,501
Less Cost of Sales	182,143	309,687
Gross Profit	762,734	535,814
Operating Expenses	180,214	98,776
Net Profit before 3 items below	582,520	437,038
Less		
Director's Fees	548,000	200,000
Management Fees	400,000	
Marketing expenses	265,294	161,607
Total adjustments	1,213,294	361,607
Net Profit/Loss as per Audited Accounts	(630,774)	75,431
Income in Advance	**1,066,661**	**390,068**



APPLICATION OF FUNDS


ITEM	MINIMUM SUBSCRIPTION ($7 million)		MAXIMUM SUBSCRIPTION ($10 million)	
Profit & Loss for the years ended	**Year 1**	**Year 2**	**Year 3**	**Year 4**
Total funds available	$7,000,000	$3,138,000	$10,000,000	$3,388,000
Working capital/Administration	$1,500,000	$1,638,000	$1,500,000	$1,888,000
Packaging Plant Acquisition			$1,500,000	
Equity investment	$1,000,000		$1,000,000	
Global sales offices		$1,500,000	$1,000,000	$1,500,000
Estimate cost of Offer	$1,070,000	-	$1,320,000	
Repayment of liabilities	$292,000		$292,000	
Total Funds Applied	**$3,862,000**	**$3,138,000**	**$6,612,000**	**$3,388,000**

PRO FORMA CAPITAL STRUCTURE

	Post $7m Raise @ 20c		Post $10m Raise @ 20c	
Pre-acquisition shares, includes 250,000 shares to John Percival & Convertible Notes	10,954,343	6.7%	10,954,343	6.1%
Zoono acquisition	94,500,000	64.3%	94,500,000	58.3%
Corporate allocation	7,560,000	5.1%	7,560,000	4.7%
Capital Raise	35,000,000	23.9%	50,000,000	30.9%
TOTAL	148,014,343	100%	163,014,202	100%
Market capitalisation ($0.20 per share)	**$29.58 million**		**$32.58 million**	

TIMETABLE

ITEM	DATE
Prospectus lodged	28 February 2017
Replacement Prospectus lodged	14 March 2017
Exposure Period ends	15 March 2017
Offer Opens	15 March 2017
Complete Capital Raising	3 April 2017
Securities resume trading	14 April 2017



SUMMARY

WHY INVEST IN ZOONO

Existing business, founded 2009, significant revenue growth over last 3 years

Existing partners, currently represented in multiple countries (20+)

Clear unique advantages over competitors

High gross margins

Low fixed costs, outsourced manufacturing and packaging

Low/no bad debt due to payment before delivery

Regulatory approvals granted in countries' of operation

Significant new opportunities currently in process

Tightly held securities, majority escrowed for 2 years

